Floatz logo
Floatz Rating
CCC52/100
Confidence
Indicative
v0.2
Sponsor
Zhen Wang, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Active Not Recruiting

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.

Same indication · Kidney Benign Neoplasm

AssetSponsorPhaseRating
Pyruvate (this asset)Zhen Wang, MDP2CCC · 52
MarcaineHans BahlmannP3B
LidocaineHans BahlmannP3B
NepentheHans BahlmannP3B
UreaZhen Wang, MDP2CCC

Other indications for Pyruvate

IndicationSponsorPhaseRating
Prostate CancerP2B · 56
Prostate CarcinomaP2B · 56
Relapsing-Remitting Multiple SclerosisP2CCC · 52

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Pyruvate in Kidney Benign Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/pyruvate-kidney-benign-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →